Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement component 1s (C1s) is a serine protease and a key enzymatic subunit of the C1 complex, which initiates the classical pathway of the complement system in humans. Upon activation by immune complexes (antigen-antibody), C1r activates C1s, which then cleaves complement proteins C4 and C2 to generate the classical pathway’s central enzyme, the classical pathway C3 convertase. Dysfunction or deficiency in complement component pathways—including mutations or deficiencies affecting *C1S*—are associated with immunodeficiencies such as systemic lupus erythematosus and hereditary angioedema; overactivation may contribute to autoimmune diseases and certain cancers. As such, it serves as both a diagnostic marker and potential therapeutic target.
Inhibition of C1s prevents cleavage of complement components C4 and C2, thereby blocking the classical complement pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement component 1s subcomponent serine protease.